Loading clinical trials...
Loading clinical trials...
The primary immunogenicity objective is to assess the antibody response and T-cell response of split-virion inactivated A (H1N1) vaccine. Participants will include up to 20 healthy persons of age 20 a...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Chinese Academy of Sciences
Collaborators
NCT04682444 · Acute Respiratory Viral Infections, Human Influenza
NCT04431050 · Human Influenza, Respiratory Syncytial Virus Infections, and more
NCT02387294 · Human Influenza
NCT03448705 · Human Influenza
NCT03572491 · Human Influenza
Institute of microbiology, Chinese Academy of Sciences
Beijing, Beijing Municipality
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions